{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:36:08Z","timestamp":1773300968639,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41388-018-0125-3","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T08:16:38Z","timestamp":1517991398000},"page":"2302-2312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN\/PD-L1 signal of lung cancer cells"],"prefix":"10.1038","volume":"37","author":[{"given":"Qi","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"125_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.soc.2016.02.011","volume":"25","author":"EC Naylor","year":"2016","unstructured":"Naylor EC, Desani JK, Chung PK. Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am. 2016;25:601\u20139.","journal-title":"Surg Oncol Clin N Am"},{"key":"125_CR2","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","volume":"11","author":"MA Socinski","year":"2016","unstructured":"Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, et al. Clinicopathologic features of advanced squamous NSCLC. J Thorac Oncol. 2016;11:1411\u201322.","journal-title":"J Thorac Oncol"},{"key":"125_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2016;2:1217\u201322.","journal-title":"JAMA Oncol"},{"key":"125_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther"},{"key":"125_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46\u201354.","journal-title":"JAMA Oncol"},{"key":"125_CR6","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1084\/jem.20161462","volume":"213","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835\u201340.","journal-title":"J Exp Med"},{"key":"125_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355\u201363.","journal-title":"Cancer Discov"},{"key":"125_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7:188\u2013201.","journal-title":"Cancer Discov"},{"key":"125_CR9","doi-asserted-by":"publisher","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra137.","journal-title":"Sci Transl Med"},{"key":"125_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med. 2015;373:23\u201334.","journal-title":"New Engl J Med"},{"key":"125_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep06331","volume":"4","author":"D Ma","year":"2014","unstructured":"Ma D, Jiang C, Hu X, Liu H, Li Q, Li T, et al. Methylation patterns of the IFN-gamma gene in cervical cancer tissues. Sci Rep. 2014;4:6331.","journal-title":"Sci Rep"},{"key":"125_CR12","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1093\/nar\/gki1001","volume":"33","author":"CA Ortmann","year":"2005","unstructured":"Ortmann CA, Burchert A, Holzle K, Nitsche A, Wittig B, Neubauer A, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res. 2005;33:6895\u2013905.","journal-title":"Nucleic Acids Res"},{"key":"125_CR13","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/j.1349-7006.2010.01581.x","volume":"101","author":"M Yamashita","year":"2010","unstructured":"Yamashita M, Toyota M, Suzuki H, Nojima M, Yamamoto E, Kamimae S, et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci. 2010;101:1708\u201316.","journal-title":"Cancer Sci"},{"key":"125_CR14","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1158\/0008-5472.CAN-04-4316","volume":"65","author":"GP Dunn","year":"2005","unstructured":"Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005;65:3447\u201353.","journal-title":"Cancer Res"},{"key":"125_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","volume":"580","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580:755\u201362.","journal-title":"FEBS Lett"},{"key":"125_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","volume":"16","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200\u20137.","journal-title":"Lancet Oncol"},{"key":"125_CR17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1535-7163.MCT-16-0454","volume":"16","author":"L Ding","year":"2017","unstructured":"Ding L, Ren J, Zhang D, Li Y, Huang X, Ji J. et al. The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects. Mol Cancer Ther. 2017;16:1068\u201379.","journal-title":"Mol Cancer Ther"},{"key":"125_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10555-015-9563-3","volume":"34","author":"A Mehta","year":"2015","unstructured":"Mehta A, Dobersch S, Romero-Olmedo AJ, Barreto G. Epigenetics in lung cancer diagnosis and therapy. Cancer Metastas- Rev. 2015;34:229\u201341.","journal-title":"Cancer Metastas- Rev"},{"key":"125_CR19","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","volume":"4","author":"J Wrangle","year":"2013","unstructured":"Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013;4:2067\u201379.","journal-title":"Oncotarget"},{"key":"125_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/10428194.2016.1219903","volume":"58","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Chang CK, He Q, Guo J, Tao Y, Wu LY, et al. Increased PD-1\/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome. Leuk Lymphoma. 2017;58:969\u201378.","journal-title":"Leuk Lymphoma"},{"key":"125_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280\u20138.","journal-title":"Leukemia"},{"key":"125_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","volume":"110","author":"J Liu","year":"2007","unstructured":"Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296\u2013304.","journal-title":"Blood"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0125-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0125-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0125-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:22Z","timestamp":1684617022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0125-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0125-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"8 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}